Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory or Relapsed Primary CNS Lymphoma
NCT00072449Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Radiographic Response Proportion. Started May 2004; status: terminated.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00072449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072449.